Piotr Pierzyński; Oliver Pohl; Line Marchand; Shari Mackens; Ulrike Lorch; Jean-Pierre Gotteland; Christophe Blockeel
Category: Publications
Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials
G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye
Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers
Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland & Oliver Pohl
The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?
Ernest Loumaye, MD, PhD
19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)
Abstract on p. 39 – part of SYMP19: Recent development in IVF
Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts
The effect of the oral oxytocin antagonist, nolasiban, on pregnancy rates in women undergoing embryo transfer following IVF
Georg Griesinger, MD, PhD; Jacques Donnez, PhD, MD; Andrew Humberstone, PhD; Paul Terrill, PhD; Oliver Pohl, DVM, MPH, MSc; Elizabeth Garner, MD, MPH; Ernest Loumaye, MD, PhD
ASRM 2020 Virtual Congress, October 2020
Poster session, abstract – Poster P. 482, page e303
Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster P-482, page e303
Efficacy and safety of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids: Results from two Phase 3 randomized clinical trials
Elizabeth A. Stewart, MD; Hugh S. Taylor, MD; Robert N. Taylor, MD, PhD; Jacques Donnez, PhD, MD; Elke Bestel, MD; Jean-Pierre Gotteland, PhD; Andrew Humberstone, PhD; Elizabeth Garner, MD, MPH
ASRM 2020 Virtual Congress, October 2020
Poster session, Late-breaking abstract – Poster P. 930, page e527
Linzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trials
Linda D. Bradley, MD; Erica E. Marsh, MD, MSCI, FACOG; Elizabeth Garner, MD, MPH
ASRM 2020 Virtual Congress, October 2020
Poster session, Late-breaking abstract – Poster P. 931, page e527
Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist
Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D.
Fertility and Sterility, Volume 114, Issue 4, 2020, Pages 739-741
The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers
O. Pohl, L. Marchand, P. Pierzyński, C. Blockeel, S. Mackens, U. Lorch, J.P. Gotteland
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on pages i83–i84
Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial
H. Taylor, J. Donnez, R. Taylor, E. Bestel, J.P. Gotteland, A. Humberstone, E. Garner
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on page i13
